Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Meta-Analysis
. 2014 Apr 20;2014(4):CD010189.
doi: 10.1002/14651858.CD010189.pub2.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults

Udo Holtick  1 , Melanie Albrecht, Jens M Chemnitz, Sebastian Theurich, Nicole Skoetz, Christof Scheid, Michael von Bergwelt-Baildon
Affiliations
Meta-Analysis

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults

Udo Holtick et al. Cochrane Database Syst Rev. .

Update in

"V体育2025版" Abstract

Background: Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an established treatment option for many malignant and non-malignant disorders VSports手机版. In the past two decades, peripheral blood stem cells replaced bone marrow as stem cell source due to faster engraftment and practicability. Previous meta-analyses analysed patients treated from 1990 to 2002 and demonstrated no impact of the stem cell source on overall survival, but a greater risk for graft-versus-host disease (GvHD) in peripheral blood transplants. As transplant indications and conditioning regimens continue to change, whether the choice of the stem cell source has an impact on transplant outcomes remains to be determined. .

Objectives: To assess the effect of bone marrow versus peripheral blood stem cell transplantation in adult patients with haematological malignancies with regard to overall survival, incidence of relapse and non-relapse mortality, disease-free survival, transplant-related mortality, incidence of GvHD and time to engraftment V体育安卓版. .

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 1), MEDLINE (from 1948 to February 2014), trial registries and conference proceedings. The search was conducted in October 2011 and was last updated in February 2014 V体育ios版. We did not apply any language restrictions. .

Selection criteria: We included randomised controlled trials (RCTs) comparing bone marrow and peripheral blood allogeneic stem cell transplantation in adults with haematological malignancies VSports最新版本. .

Data collection and analysis: Two review authors screened abstracts and extracted and analysed data independently. We contacted study authors for additional information V体育平台登录. We used the standard methodological procedures expected by The Cochrane Collaboration. .

Main results: We included nine RCTs that met the pre-defined selection criteria, involving a total of 1521 participants. Quality of data reporting was heterogeneous among the studies. Overall, the risk of bias in the included studies was low. For the primary outcome overall survival, our analysis demonstrated comparable results between bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) (six studies, 1330 participants; hazard ratio (HR) 1. 07; 95% CI 0. 91 to 1. 25; P value = 0. 43; high-quality evidence). Disease-free survival (six studies, 1225 participants; HR 1. 04; 95% CI 0. 89 to 1. 21; P value = 0. 6; moderate-quality of evidence) and non-relapse or transplant-related mortality (three studies, 758 participants; HR 0. 98; 95% CI 0. 76 to 1. 28; P = 0. 91; high-quality evidence) were also comparable between transplantation arms. In the related-donor setting, data from two of eight studies with 211 participants (21%) indicated a higher relapse incidence in participants transplanted with bone marrow stem cells rather than peripheral blood stem cells (HR 2. 73; 95% CI 1. 47 to 5. 08; P value = 0. 001). There was no clear evidence of a difference in relapse incidence between transplantation groups in unrelated donors (HR 1. 07; 95% CI 0. 78 to 1. 47; P value = 0. 66). The difference between the donor-related and -unrelated subgroups (P-value = 0. 008) was considered to be statistically significant. BMT was associated with lower rates of overall and extensive chronic GvHD than PBSCT (overall chronic GvHD: four studies, 1121 participants; HR 0. 72; 95% CI 0. 61 to 0. 85; P value = 0. 0001, extensive chronic GvHD: four studies, 765 participants; HR 0. 69; 95% CI 0. 54 to 0. 9; P value = 0. 006; moderate-quality evidence for both outcomes). The incidence of acute GvHD grades II to IV was not lower (six studies, 1330 participants; HR 1. 03; 95% CI 0. 89 to 1. 21; P value = 0. 67; moderate-quality evidence), but there was a trend for a lower incidence of grades III and IV acute GvHD with BMT than with PBSCT (three studies, 925 participants; HR 0. 75; 95% CI 0. 55 to 1. 02; P value = 0. 07; moderate-quality evidence). Times to neutrophil and platelet engraftment were longer with BMT than with PBSCT (neutrophil: five studies, 662 participants; HR 1. 96; 95% CI 1. 64 to 2. 35; P value < 0. 00001; platelet: four studies, 333 participants; HR 2. 17; 95% CI 1. 69 to 2. 78; P value < 0. 00001). VSports注册入口.

Authors' conclusions: This systematic review found high-quality evidence that overall survival following allo-HSCT using the current clinical standard stem cell source - peripheral blood stem cells - was similar to that following allo-HSCT using bone marrow stem cells in adults with haematological malignancies. We found moderate-quality evidence that PBSCT was associated with faster engraftment of neutrophils and platelets, but a higher risk of GvHD (in terms of more overall and extensive chronic GvHD) V体育官网入口. There was an imprecise effect on relapse and on severe (grades III to IV) acute GvHD. Quality of life, which is severely affected by GvHD, was not evaluated. Against the background of transplantation practices that have clearly changed over the past 10 to 15 years, our aim was to provide current data on the best stem cell source for allo-HSCT, by including the results of recently conducted trials. Our review includes participants recruited up to 2009, a proportion of whom were older, had received reduced-intensity conditioning regimens or had been transplanted with stem cells from unrelated donors. However, only one, large, study included relatively recently treated participants. Nevertheless, our findings are comparable to those of previous meta-analyses suggesting that our results hold true for today's practice. .

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Forest plot of comparison: 1 BMT vs PBSCT, outcome: 1.1 Overall survival.
4
4
Forest plot of comparison: 1 BMT vs PBSCT, outcome: 1.2 Disease free survival.
5
5
Forest plot of comparison: 1 BMT vs PBSCT, outcome: 1.3 Incidence of relapse.
6
6
Forest plot of comparison: 1 BMT vs PBSCT, outcome: 1.5 Incidence of overall chronic GvHD.
7
7
Forest plot of comparison: 1 BMT vs PBSCT, outcome: 1.9 Time to neutrophil engraftment.
8
8
Forest plot of comparison: 1 BMT vs PBSCT, outcome: 1.10 Time to platelet engraftment.
1.1
1.1. Analysis
Comparison 1 BMT vs PBSCT, Outcome 1 Overall survival.
1.2
1.2. Analysis
Comparison 1 BMT vs PBSCT, Outcome 2 Disease free survival.
1.3
1.3. Analysis
Comparison 1 BMT vs PBSCT, Outcome 3 Incidence of relapse.
1.4
1.4. Analysis
Comparison 1 BMT vs PBSCT, Outcome 4 Transplant related mortality.
1.5
1.5. Analysis
Comparison 1 BMT vs PBSCT, Outcome 5 Incidence of overall chronic GvHD.
1.6
1.6. Analysis
Comparison 1 BMT vs PBSCT, Outcome 6 Incidence of extensive chronic GvHD.
1.7
1.7. Analysis
Comparison 1 BMT vs PBSCT, Outcome 7 Incidence of acute GvHD grade II‐IV.
1.8
1.8. Analysis
Comparison 1 BMT vs PBSCT, Outcome 8 Incidence of acute GvHD grade III‐IV.
1.9
1.9. Analysis
Comparison 1 BMT vs PBSCT, Outcome 9 Time to neutrophil engraftment.
1.10
1.10. Analysis
Comparison 1 BMT vs PBSCT, Outcome 10 Time to platelet engraftment.
See this image and copyright information in PMC

References

References to studies included in this review

Anasetti 2012 {published data only}
    1. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral‐blood stem cells versus bone marrow from unrelated donors. The New England Journal of Medicine 2012;367(16):1487‐96. - "VSports app下载" PMC - PubMed
Couban 2002 {published data only}
    1. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson‐Jan K, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002;100(5):1525‐31. - PubMed
Friedrichs 2010 {published data only}
    1. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, et al. Long‐term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncology 2010;11(4):331‐8. - PubMed
    1. Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, et al. Filgrastim‐mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3‐year results from the EBMT randomized trial. Haematologica 2005;90(5):643‐8. - PubMed
    1. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. Transplantation of mobilized peripheral blood cells to HLA‐identical siblings with standard‐risk leukemia. Blood 2002;100(3):761‐7. - PubMed
Heldal 2003 {published data only}
    1. Abrahamson IW, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord GE. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft‐versus‐host disease. Haematologica 2005;90(1):86‐93. - PubMed
    1. Heldal D, Brinch L, Tjonnfjord G, Solheim BG, Egeland T, Albrechtsen D, et al. Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5‐year follow‐up in a single centre study. Bone Marrow Transplantation 2003;32(3):257‐64. - PubMed
Mahmoud 1999 {published data only}
    1. Mahmoud HK, Fahmy OA. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 1999;24:355‐58. - PubMed (V体育官网入口)
Mielcarek 2011 {published data only}
    1. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral‐blood cells from HLA‐identical relatives in patients with hematologic cancers. The New England Journal of Medicine 2001;344(3):175‐81. - PubMed
    1. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, et al. Comparison of chronic graft‐versus‐host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long‐term follow‐up of a randomized trial. Blood 2002;100(2):415‐9. - PubMed
    1. Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, et al. Long‐term outcomes after transplantation of HLA‐identical related G‐CSF‐mobilized peripheral blood mononuclear versus bone marrow. Blood 2012;119:2675‐8. - PMC - PubMed
    1. Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biology of Blood and Marrow Transplantation 2005;11(2):85‐92. - PubMed
Mohty 2002 {published data only}
    1. Blaise D, Keuntz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim‐primed blood cell allogeneic transplantation in patients with early‐stage leukemia: a report from the Société Française de Greffe de Moelle. Journal of Clinical Oncology 2000;18(3):537‐46. - "VSports手机版" PubMed
    1. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, et al. Chronic graft‐versus‐host disease after allogeneic blood stem cell transplantation: long‐term results of a randomized study. Blood 2002;100(9):3128‐34. - PubMed
Powles 2002 {published data only}
    1. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone‐marrow stem‐cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000;355(9211):1231‐7. - PubMed
Vigorito 2001 {published data only}
    1. Souza CA, Durães MI, Vigorito AC, Penteado Aranha FJ, Oliveira GB, De Brito, et al. Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft. Haematologica 2002;87:1281‐85. - PubMed
    1. Nucci M, Andrade F, Vigorito A, Trabasso P, Aranha JF, Maiolino A, et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transplant Infectious Disease 2003;5(4):167‐73. - PubMed
    1. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplantation 1998;22(12):1145‐51. - PubMed
    1. Vigorito AC, Marques Junior JF, Aranha FJ, Oliveira GB, Miranda EC, Souza CA. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Haematologica 2001;86(6):665‐6. - PubMed

References to studies excluded from this review

Bacigalupo 2012 {published data only}
    1. Bacigalupo A, Socié G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 2012;97(8):1142‐8. - PMC - PubMed
Champlin 2000 {published data only}
    1. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95(12):3702‐9. - PubMed
Cornelissen 2003 {published data only}
    1. Cornelissen JJ, van der Holt B, Petersen EJ, Vindelov L, Russel CA, Höglund M et al. A randomized multicenter comparison of CD34(+)‐selected progenitor cells from blood vs from bone marrow in recipients of HLA‐identical allogeneic transplants for hematological malignancies. Experimental Hematology 2003;31(10):855‐64. - VSports注册入口 - PubMed
Favre 2003 {published data only}
    1. Favre G, Beksaç M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplantation 2003;32(9):873‐80. - PubMed
Kirschbaum 2012 {published data only}
    1. Kirschbaum M, O’Donnell M, Spielberger R, Bhatia R, Pullarkat V, Stein A, et al. Peripheral blood stem cells vs bone marrow for matched sibling transplant in AML and ALL remission [abstract]. Blood 2012;104(11):3321.
Morton 2001 {published data only}
    1. Morton J, Hutchins C, Durrant S. Granulocyte‐colony‐stimulating factor (G‐CSF)‐primed allogeneic bone marrow: significantly less graft‐versus‐host disease and comparable engraftment to G‐CSF‐mobilized peripheral blood stem cells. Blood 2001;98(12):3186‐91. - VSports - PubMed
Pidala 2009 {published data only}
    1. Pidala J, Anasetti C, Kharfan‐Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2009;15(11):1415‐21. - PubMed
Robinet 2003 {published data only}
    1. Robinet E, Lapierre V, Tayebi H, Kuentz M, Blaise D, Tiberghien P. Blood versus marrow hematopoietic allogeneic graft. Transfusion and Apheresis Science 2003;29(1):53‐9. - PubMed
Storek 2001 {published data only}
    1. Storek J, Dawson MA, Storer B, Stevens‐Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97(11):3380‐9. - PubMed

Additional references

Appelbaum 2007
    1. Appelbaum FR. Hematopoietic‐cell transplantation at 50. The New England Journal of Medicine 2007;357(15):1472‐5. - PubMed
Baldomero 2011
    1. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation 2011;46(4):485‐501. - PubMed
Bensinger 2001
    1. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral‐blood cells from HLA‐identical relatives in patients with hematologic cancers. The New England Journal of Medicine 2001;344(3):175‐81. - PubMed
Bensinger 2012
    1. Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. Current Opinion in Oncology 2012;24(2):191‐6. - PMC - PubMed
Blaise 2000
    1. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim‐primed blood cell allogeneic transplantation in patients with early‐stage leukemia: a report from the Société Française de Greffe de Moelle. Journal of Clinical Oncology 2000;18(3):537‐46. - PubMed
Brunner 2013
    1. Brunner AM, Kim HT, Coughlin E, Alyea EP, Armand P, Ballen KK, et al. Outcomes of patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation 2013;19(9):1374‐80. - PubMed
Chang 2012
    1. Chang YJ, Weng CL, Sun LX, Zhao YT. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta‐analysis based on time‐to‐event data from randomized controlled trials. Annals of Hematology 2012;91(3):427‐37. [PUBMED: 21789620] - "VSports最新版本" PubMed
Confer 2007
    1. Confer DL, Miller JP. Long‐term safety of filgrastim (rhG‐CSF) administration. British Journal of Haematology 2007;137:77‐8. - "V体育安卓版" PMC - PubMed
Confer 2009
    1. Confer DL, Miller JP, Chell JW. Bone marrow and peripheral blood cell donors and donor registries. In: Frederick R. Appelbaum, Stephen J. Forman, Robert S. Negrin, Karl G. Blume editor(s). Thomas' Hematopietic Cell Transplantation. 4th Edition. Oxford, UK: Wiley‐Blackwell, 2009. doi: 10.1002/9781444303537.ch38:544‐58.
de Fabritiis 2001
    1. de Fabritiis P, Iori AP, Mengarelli A, Gozzer M, Ferrazza G, De Propris MS, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G‐CSF. Transfusion 2001;41(2):190‐5. - "V体育ios版" PubMed
De Souza 2002
    1. Souza CA, Durães MI, Vigorito AC, Penteado Aranha FJ, Oliveira GB, De Brito, et al. Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft. Haematologica 2002;87(12):1281‐5. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Eapen 2007
    1. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft‐versus‐host disease without improved survival. Biology of Blood and Marrow Transplantation 2007;13(12):1461‐8. - "VSports" PMC - PubMed
Ferrera 2009
    1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft‐versus‐host disease. Lancet 2009;373(9674):1550‐61. - PMC - PubMed
Filipovich 2005
    1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation 2005;11(12):945‐56. - PubMed
Gluckman 2006
    1. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Current Opinion in Immunology 2006;18(5):565‐70. - PubMed
Glucksberg 1974
    1. Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HLA‐matched sibling donors. Transplantation 1974;18(4):295‐304. - PubMed
Goldberg 2013
    1. Goldberg JD, Giralt S. Assessing response of therapy for acute and chronic graft‐versus‐host disease. Expert Reviews in Hematology 2013;6(1):103‐7. - PubMed
Gratwohl 2007
    1. Gratwohl A, Baldomero H, Frauendorfer K, Urbano‐Ispizua A, Niederwieser D. Results of EBMT activity survey 2005 on hematopoietic stem cell transplantation: Focus on increasing use of unrelated donors. Bone Marrow Transplantation 2007;39:71‐87. - PubMed
Gratwohl 2009
    1. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplantation 2009;43(4):275‐91. - "V体育安卓版" PubMed
Gratwohl 2013
    1. Gratwohl A, Baldomero H, Gratwohl M, Aljurf MD, Bouzas LF, Horowitz M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 2013;98(8):1282‐90. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐"VSports最新版本" handbook.org.
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011c
    1. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐V体育官网入口 - handbook.org.
Horwitz 2006
    1. Horwitz ME, Sullivan KM. Chronic graft‐versus‐host disease. Blood Reviews 2006;20(1):15‐27. - PubMed
Jenq 2010
    1. Jenq RR, Brink MRM. Allogeneic hematopoietic stem cell transplantation: individualized stem cell and immunotherapy of cancer. Nature Reviews of Cancer 2010;10(3):213‐21. - PubMed
Kalbfleisch 1980
    1. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data . New York, NY, USA: John Wiley, 1980.
Kuzmina 2012
    1. Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P, et al. Significantly worse survival of patients with NIH‐defined chronic graft‐versus‐host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012;26(4):746‐56. - PubMed
Labopin 2003
    1. Labopin M, Iacobelli S. Statistical guidelines for EBMT. "VSports" http://www.ebmt.org/1WhatisEBMT/Op_Manual/OPMAN_StatGuidelines_oct2003.pdf (accessed 01 March 2012).
Labopin 2009
    1. Labopin M, Latouche A, Suciu S, Santucci A, Canals C, Iacobelli S, et al. Definitions and evaluation of endpoints following stem cells transplantation ‐ recommendation from the European group for Blood and Marrow transplantation (EBMT). CLINT, Work Package 5 2009. http://portal.ebmt.org/sites/clint2/clint/Documents/Statistical%20Endpoi... (accessed 25 March 2014).
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org (VSports).
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006‐12. - "VSports注册入口" PubMed
Nagler 2012
    1. Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced‐intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 2012;18(9):1422‐9. - V体育安卓版 - PubMed
Norkin 2012
    1. Norkin M, Hsu JW, Wingard JR. Quality of life, social challenges, and psychosocial support for long‐term survivors after allogeneic hematopoietic stem‐cell transplantation. Seminars in Hematology 2012;49(1):104‐9. - PubMed
Paczesny 2009
    1. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplantation 2009;45(1):1‐11. - PMC - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Pasquini 2013
    1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available at: http://www.cibmtr.org.
Petersdorf 2001
    1. Petersdorf E, Hansen J, Martin P, Woolfrey A, Malkki M, Gooley T, et al. Major‐histocompatibility‐complex class I alleles and antigens in hematopoietic‐cell transplantation. The New England Journal of Medicine 2001;345(25):1794‐800. - "V体育ios版" PubMed
Pidala 2009a
    1. Pidala J, Anasetti C, Kharfan‐Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2009;15(11):1415‐21. - PubMed
Pidala 2009b
    1. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009;114(1):7‐19. - PMC - PubMed
Pollack 2009
    1. Pollack SM, O’Connor TP, Hashash J, Tabbara IA. Nonmyeloablative and reduced‐intensity conditioning for allogeneic hematopoietic stem cell transplantation. American Journal of Clinical Oncology 2009;32(6):618‐28. - PubMed
Review Manager 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Ringden 2009
    1. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft‐versus‐cancer effect. British Journal of Haematology 2009;147(5):614‐33. - PubMed
Ringden 2012
    1. Ringden O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. Journal of Internal Medicine 2012;272(5):472‐83. - PubMed
Schmitz 2002
    1. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA‐identical siblings with standard‐risk leukemia. Blood 2002;100(3):761‐7. - V体育官网入口 - PubMed
Schmitz 2005
    1. Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Filgrastim‐mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3‐year results from the EBMT randomized trial. Haematologica 2005;90(5):643‐8. - "V体育安卓版" PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Siddiq 2009
    1. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006406.pub2] - DOI - PubMed
Sorror 2011
    1. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long‐term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. Journal of the American Medical Association 2011;306(17):1874‐83. - PMC - PubMed
Stem Cell Trialists' Collaborative Group 2005
    1. Stem Cell Trialists' Collaborative Croup. Allogeneic peripheral blood stem‐cell compared with bone marrow transplantation in the management of hematological malignancies: an individual patient data meta‐analysis of nine randomised trials. Journal of Clinical Oncology 2005;23(22):5074‐87. - PMC - PubMed
Stem Cell Trialists' Collaborative Group 2006
    1. Stem Cell Trialists' Collaborative Group. Individual patient data meta‐analysis of allogeneic peripheral blood stem cell transplant vs. bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of the day 11 methotrexate administration. Bone Marrow Transplantation 2006;38(6):539‐46. - "VSports在线直播" PMC - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐VSports手机版 - handbook.org.
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. - PMC - PubMed
Vigorito 1998
    1. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplantation 1998;22(12):1145‐51. - V体育官网 - PubMed
Weisdorf 2012
    1. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft‐versus‐host disease induced graft‐versus‐leukemia effect: greater impact on relapse and disease‐free survival after reduced intensity conditioning. Biology of Blood and Marrow Transplantation 2012;18(11):1727‐33. - PMC - PubMed
Wood 2013
    1. Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, et al. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplantation 2013;48(11):1429‐36. - PMC - PubMed

MeSH terms

LinkOut - more resources